There are 2789 resources available
1307P - Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
Presenter: Yasushi Goto
Session: ePoster Display
1232P - Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
Presenter: Hollie Bailey
Session: ePoster Display
1233P - EGFR-TKIs compared with radiotherapy for patients of stage IV lung adenocarcinoma with EGFR mutation
Presenter: Yuxiang Wang
Session: ePoster Display
1234P - Impact of radiotherapy pattern on the prognosis of stage IV lung adenocarcinomas harboring EGFR mutations
Presenter: Yingyun Zhang
Session: ePoster Display
1235P - Comparative study between two 17-gray fractions versus thirteen 39-gray fractions palliative thoracic radiotherapy in advanced non-small cell lung carcinoma
Presenter: Syeda Tasmia
Session: ePoster Display
1236P - Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
Presenter: Arsela Prelaj
Session: ePoster Display
1237P - Gut microbiome profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
Presenter: Woraseth Saifon
Session: ePoster Display
1238P - AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients
Presenter: Baohui Han
Session: ePoster Display
1240P - Targeting exon 18 EGFR alterations in non-small cell lung cancer: A patient-level analysis of published data
Presenter: Mehmet Goksu
Session: ePoster Display